等待开盘 09-08 09:30:00 美东时间
+0.060
+0.20%
今日重点评级关注:Ascendiant Capital:维持PAVmed"买入"评级,目标价从56美元升至57美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从9.25美元升至9.5美元
08-28 16:15
今日重点评级关注:摩根大通:维持Ultragenyx Pharmaceutical"超配"评级,目标价从75美元升至80美元;瑞杰金融:维持英伟达"强力买入"评级,目标价从330美元升至352美元
08-26 08:37
Jefferies analyst Jonathan Petersen initiates coverage on Curbline Properties (NYSE:CURB) with a Buy rating and announces Price Target of $36.
08-25 23:03
今日重点评级关注:HC Wainwright & Co.:维持Enlivex"买入"评级,目标价从20美元升至80美元;Canaccord Genuity:维持Pharming Group NV Sponsored ADR"买入"评级,目标价从37美元升至38美元
08-04 11:45
今日重点评级关注:古根海姆:维持ProMIS Neurosciences"买入"评级,目标价从35美元升至69美元;BTIG:维持Cullinan Therapeutics"买入"评级,目标价从38美元升至39美元
07-30 11:45
Keybanc analyst Todd Thomas maintains Curbline Properties (NYSE:CURB) with a Overweight and raises the price target from $32 to $34.
07-29 22:03
Curbline Properties (NYSE:CURB) raises FY2026 FFO guidance from $1.20-$1.23 to $1.24-$1.26 vs $1.22 analyst estimate..
07-28 18:31
Curbline Properties (NYSE:CURB) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.29 by 3.33 percent. This is a 24 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $63.296 million wh...
07-28 18:30
今日重点评级关注:HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从50美元升至69美元;高盛:维持Taysha Gene Therapies"买入"评级,目标价从11美元升至13美元
07-22 11:35
Piper Sandler analyst Alex Goldfarb maintains Curbline Properties (NYSE:CURB) with a Overweight and raises the price target from $32 to $39.
07-22 01:30